Malin rethinks next move on Poseida as new options emerge

Malin is considering options other than a stock market listing to cash in on its stake in drug company Poseida – including a potential sale.

Malin owns a third of Poseida, which develops treatments for cancer using gene and cell therapy. In January the company announced it was preparing to float on the US stock market this year.

However, speaking to The Sunday Business Post, Darragh Lyons, Malin’s chief business and finance officer, ...